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AbstrAct
Objectives in year 2016, Danish national guidelines 
included a mandatory switch of patients with inflammatory 
rheumatic diseases treated with originator etanercept 
(eta) to biosimilar SB4 in routine care. We aimed to explore 
if switching lead to increased healthcare utilisation and 
costs.
Methods Observational cohort study. adult patients 
who switched from eta to SB4 were identified in the 
Danish nationwide DanBiO registry. in the national 
Patient registry, we identified health utilisation (hospital 
admissions/hospital days/outpatient visits/prescription 
medication use) and comorbidities. estimation of health 
utilisation included average use and costs 1 year before/
after switch, changes after the switch, and whether 
patient characteristics affected changes. analyses were 
by adjusted two-step gamma distributed regression 
models, and for changes over time a generalized 
estimation equations (gee) model was applied. impact of 
comorbidities was explored as interaction terms in the 
model. Medication costs of eta and SB4 were not included 
in model.
Results 1620 patients were included (mean age 55 years 
(SD 14.7), 40% male). costs before and after switching 
were mainly driven by outpatient visits (67%/72% of 
all costs). Monthly fluctuations of costs were similar 
before/after switch. after switching, use (8%) and costs 
(7%) of outpatient services increased, whereas costs 
of admissions (55%) and medication (5%) decreased. 
Patients with longer eta treatment duration had an 
increase in use and costs of healthcare resources, whereas 
gender and comorbidities had no impact. Higher age was 
associated with an increase in costs of inpatient services.
Conclusion We demonstrated no obvious changes in 
overall use and costs of healthcare services following 
switch from originator to biosimilar etanercept.
InTROduCTIOn
The biological disease modifying antirheu-
matic treatments (bDMARDs) have trans-
formed the treatment options among patients 
with inflammatory rheumatic diseases other-
wise refractory to conventional synthetic (cs-)
DMARDs. In recent years, patents on widely 
prescribed bDMARDs have expired and 
consequently cheaper biosimilar products are 
emerging.1
Randomised studies of patients on stable 
treatment with originator etanercept (ETA) 
who switched to the corresponding biosim-
ilar have demonstrated no negative impact 
of such a non-medical switch on safety and 
treatment efficacy.2 3 This has created a finan-
cial incentive for healthcare payers to stimu-
late switching with the potential of reduced 
medication costs. This would potentially allow 
more patients to be treated.4 The economic 
benefit from switching may potentially be 
Key messages
What is already known about this subject?
 ► Mandatory switching from originator to a cor-
responding cheaper biosimilar biological agent 
(=non-medical switch) has been suggested in in-
flammatory rheumatic diseases.
 ► the economic benefit might potentially be out-
weighed by extra costs (eg, patient education, closer 
monitoring).
What does this study add?
 ► We found no obvious changes in healthcare utilisa-
tion and costs in 1620 Danish patients who were 
switched from originator to biosimilar etanercept in 
routine care.
How might this impact on clinical practice?
 ► non-medical etanercept switching of long-term 
treated patients with inflammatory rheumat-
ic disease has no short-term negative economic 
consequences.
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partly outweighed by extra costs if the number of outpa-
tient visits and contacts to healthcare providers rises 
due to for example, patient education or closer moni-
toring.5–8 However, existing pharmaco-economic and 
health-economic studies have focused mainly on drug 
prices and the direct cost of treatment,9 whereas overall 
utilisation of healthcare and associated costs have not 
been addressed.
Denmark has had a rapid uptake of biosimilar products 
reflecting strong adherence to the national guidelines.10 
The switches have been prospectively registered in the 
nationwide DANBIO registry11 12 and linkage to other 
national registries allows for detailed study of any impact 
of treatment changes.11 13 14 Thus, in year 2017 Danish 
national guidelines recommended switch of all patients 
with inflammatory rheumatic diseases treated with ETA 
to the corresponding biosimilar SB4.10 The switch was 
mandatory, that is, neither the physician nor the patient 
had any say in the matter—– only very specific individual 
patient considerations should prevail switching.10 The 
recommendation was due to economic reasons as SB4 
upon marketing cost 49% less than ETA. A similar switch 
occurred in 2016 for infliximab,15 where we found no 
major changes in the number of healthcare services and 
the visit rate provided in rheumatology outpatient care 
6 months following the switch among 769 patients with 
inflammatory arthritis.16
Infliximab and etanercept have different routes of 
administration (intravenous vs subcutaneous) and 
may thus potentially be used by patients with different 
demographic and disease characteristics. Furthermore, 
the perception of biosimilars among healthcare profes-
sionals and patients may change over time.6 17 Thus, 
experience regarding switch outcomes from infliximab 
cannot readily be extrapolated to etanercept. Thus, the 
aim of this study was to explore healthcare utilisation 
and costs 1 year before and after the Danish nationwide 
mandatory switch from ETA to biosimilar SB4 etanercept 
among patients with inflammatory rheumatic diseases 
followed in routine care. Furthermore, we wanted to 
explore if selected patient and disease characteristics 
affected outcomes. Switch patterns and the impact of the 
switch on disease activity and retention to SB4-treatment 
have been published.12
MeTHOds and MaTeRIals
study design
A register-based before-after switching health cost study 
of Danish adult patients with rheumatoid arthritis, psori-
atic arthritis or axial spondyloarthritis followed in the 
DANBIO registry who switched from ETA to SB4 in 2016 
(=switchers). Patients served as their own controls in the 
statistical analyses of use before and after switch.
The analysis of health utilisation and costs was divided 
in three parts: (1) an estimation of average use before 
and after the switch, (2) an analysis of change in use after 
the switch and (3) investigation of how patient character-
istics affected change in use.
study population and study period
Switchers during the time period 1 April 2016 to 1 January 
2017 were identified in the Danish nationwide DANBIO 
registry as previously described.12 DANBIO prospectively 
collects information from Danish departments of rheu-
matology regarding treatment and outcomes in patients 
with inflammatory arthritis.11 The index date was the 
date of the switch. The preperiods and postperiods were 
defined as 1 year (=52 weeks) prior to and 1 year following 
the index date, respectively.
study variables
Health utilisation and health costs 1 year before versus 
1 year after the switch (including the index date) were 
identified and compared.
Health utilisation
Health utilisation was measured as inpatient services 
(hospital admissions, hospital days), outpatient visits 
and use of medication other than etanercept (measured 
as defined daily dose (DDD)).18 By use of unique civil 
registration numbers (CPR), these data were obtained 
through linkage to national registries: information on 
hospital contacts was obtained from The National Patient 
Registry (NPR), which has virtually complete data on 
inpatient and outpatient contacts in specialised care.14 
Information about the total sale of prescribed medicinal 
products in Denmark was obtained from The Danish 
Prescription Drug Register.19
Health costs
The cost analysis was divided into costs for inpatient, 
outpatient and primary sector contacts as well as medi-
cation other than etanercept. Costs for inpatient and 
outpatient hospital treatment were calculated according 
to the activity-based fees (DRG and DAGS tariffs).20 Inpa-
tient and outpatient costs were both divided into costs 
related to (1) the musculoskeletal system and connective 
tissue (action diagnoses, ICD10 codes M00-M99) and (2) 
other diseases.
The primary sector includes general practitioners, 
other specialist doctors, physiotherapists, chiroprac-
tors and foot specialists. The Health Insurance Register 
contains information on the settlement of health insur-
ance services between the hospital owners (Danish 
Regions) and providers covered by the health insur-
ance that is, general practitioners, practicing specialists, 
dentists, psychologists and so on which was used to esti-
mate the costs of health utilisation.21
Medication was grouped into pain medication (non-ste-
roid anti-inflammatory drugs, NSAIDs (ATC-codes M01A, 
N02B) and opioids (N02A)) and other medication. We 
looked at cost of the medication and the DDD of medica-
tion total costs.18 Only medication handled by prescrip-
tion was included. Thus, ETA and SB4 were not included 
because biological treatments in Denmark are provided 
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Table 1 Baseline characteristics of included patients (n=1620)
Age, years, mean (SD) 55 (14.7)
Gender, male, n (%) 655 (40.4)
Duration of ETA, n (%) 1 year 78 (4.8)
  2 years 106 (6.5)
  3 years 176 (10.9)
  4 years 207 (12.8)
  5 years 205 (12.7)
  >5 years 848 (52.3)
Comorbidities*, n (%) 1 Certain infectious and parasitic diseases 42 (2.6)
  2 Neoplasms 78 (4.8)
  3 Diseases of blood and blood forming organs 26 (1.6)
  4 Endocrine, nutritional, metabolic diseases 134 (8.3)
  5 Mental and behavioural disorders 17 (1.0)
  6 Diseases of the nervous system 67 (4.1)
  7 Diseases of eye and adnexa 72 (4.4)
  8 Diseases of ear and mastoid 35 (2.2)
  9 Diseases of circulatory system 175 (10.8)
  10 Diseases of respiratory system 109 (6.7)
  11 Diseases of digestive system 157 (9.7)
  12 Diseases of skin and subcutaneous system 143 (8.8)
  13 Diseases of musculoskeletal system and connective tissue 1598 (98.6)
  14 Diseases of genitourinary system 113 (7.0)
  15 Pregnancy, childbirth and puerperium 15 (0.9)
  16 Conditions in perinatal period –
  17 Congenital malformations, deformations, chromosomal abnormalities 16 (1.0)
  18 Symptoms, signs and abnormal clinical etc 199 (12.3)
  19 Injury, poisoning, consequences of external causes 185 (11.4)
  20 External causes of morbidity and mortality –
  21 Factors influencing health status and contact with health services 863 (53.3)
*WHO diagnosis chapters 12–24 months previously.
ETA, originator etanercept.
free of charge directly to the patients by the outpatient 
rheumatology clinics.
changes in utilisation and costs
To detect changes in utilisation and costs over time, 
all contacts and costs were identified in the 52 weeks 
preindex and postindex date. The post period included 
the index date.
Patient characteristics
Information regarding age, gender, death and emigra-
tion was identified in the Danish civil registration system. 
For each patient, previous comorbidities were identified 
through healthcare utilisation (in-hospital and outpa-
tient) in the time-window from 12 to 24 months prior to 
the index-date. Comorbidities were coded according to 
the WHO-system in 21 chapters/groups.22
Variables from DANBIO included whether treatment 
with SB4 was withdrawn within 0–180 days from index 
date (yes/no), and duration of ETA treatment before 
index date (years, divided in 0–1/2/3/4/5/>5 years).
ethics and dissemination
The study was approved by the Danish data protection 
agency. According to Danish law, approval from ethics 
committees is not necessary for registry research.
statistical analyses
All analyses were performed in SAS V.9.3. A p value <0.05 
was considered statistically significant.
Health utilisation and costs before and after switch
To analyse the yearly health utilisation and costs and we 
used a two-step gamma distributed regression model23 
where we controlled for age, gender, death in the post 
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Figure 1 Monthly average costs 12 months before and 
after switch from originator to biosimilar etanercept (n=1620 
patients). Black dotted vertical line illustrates time of switch. 
(A) Inpatient and outpatient costs, (B) prescription medication 
costs.
period, SB4 withdrawal within 180 days, duration of ETA 
before index date and previous comorbidities (ie, each 
of the 21 comorbidity groups excluding musculoskeletal 
were included as dummies; a patient could have more 
than one comorbidity dummy). From these regressions, 
costs were predicted before and after switch for a patient 
characterised by: being female, 55 years old, not dead in 
the postperiod, not stopped within 180 days, previous 
duration of ETA treatment >5 years and with no comor-
bidities (excluding musculoskeletal) 12–24 months 
before index date (=adjusted, predicted).
analysis of change in costs after switch
To analyse whether there were changes in costs over time, 
we included a dummy variable (after=1) in the model. 
The estimate for this dummy showed whether there 
were changes over time (before-after). Since the costs 
before and after included repeated measures in the same 
patients, the costs at the two time-points were correlated. 
Thus, to ensure robust standard errors, we applied a GEE 
model.24
analysis of any influence of population characteristics on change 
in health utilisation and costs after switch
To analyse if population characteristics had any influ-
ence on the changes in health utilisation and costs over 
time, we extended the statistical model to include inter-
actions terms. The regression model adjusted for the 
following main effects: gender, age, dead in post period, 
duration of ETA before index date, withdrawn SB4 treat-
ment within 180 days, and previous comorbidities. The 
following interaction terms were included in the model: 
after*gender, after*age, after*duration of ETA before 
index date, and after*stopped SB4 within 180 days.
To estimate whether previous comorbidities had any 
influence on health utilisation and costs after the switch, 
the regression (controlled for after, gender, age, dead in 
post period, stopped SB4 within 180 days) we performed 
a regression for each of the 21 WHO chapters one at a 
time. Furthermore, an interaction term for each of the 21 
WHO chapters were included one by one in the model 
(after*WHO_chapter) to see if having a diagnosis from 
each particular WHO chapter influenced change in costs.
ResulTs
Patient cohort
Of the 1623 patients in DANBIO who switched from 
ETA to SB4, three patients were excluded due to data 
errors (double registration and missing demographic 
data). Thus, 1620 patients were included in the anal-
yses (table 1). A total of 848 patients (52.3%) had been 
treated with ETN >5 years before index date.
Within 180 days after the switch, 199 patients (12.3%) 
stopped SB4. Within 1 year after the switch, 11 patients 
died (0.7%).
average health costs and health utilisation before and after the 
switch
Outpatient services represented the largest share of 
the total health costs before and after switching (mean 
number per patient 12.3 visits and 13.3 visits, respectively, 
table 2). Unadjusted, the outpatient costs represented 
nearly 70% of total costs whereas inpatient costs was 17%, 
primary sector costs 10% and medication 6%. The distri-
bution was similar before/after switch and in the unad-
justed/adjusted analyses.
The majority (≈80%) of outpatient costs were related 
to diseases of the musculoskeletal system and connec-
tive tissue whereas it for inpatient costs was the minority 
(21%–24% of costs). In general, the adjusted health 
costs were lower than the unadjusted costs, for example, 
number of inpatient admissions, hospital days and inpa-
tient costs (table 2) due to the adjustment for no previous 
comorbidities.
There was in increase in outpatient health costs during 
the first month after switch (figure 1A). This time-period 
included date of switch (=index date) and illustrated that 
patients often received a service in outpatient care in 
relation to switching. Health costs (inpatient and outpa-
tient) and costs of medication fluctuated throughout 
the 2-year interval with no clear pattern (figure 1A,B). 
Similar results were seen for primary sector (not shown).
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Table 3 (A) Changes in health utilisation, and (B) changes in costs per patient 12 months before and after switch including 
adjusting variables*
After*
Exp (estimate), 95% CI P value
(A) Changes in health utilisation per patient
  Inpatient services Number of inpatient admissions 0.45 (0.37 to 0.54) <0.0001
Number of days in hospital 0.36 (0.25 to 0.51) <0.0001
  Outpatient Number of outpatient visits 1.08 (1.05 to 1.11) <0.0001
  Medication† Pain medication, DDD 0.99 (0.96 to 1.03) 0.702
Other medication 1.03 (1.00 to 1.05) 0.051
Total 1.02 (1.00 to 1.04) 0.100
(B) Changes in health costs per patient
  Inpatient services Diseases of the musculoskeletal system and connective tissue 0.70 (0.44 to 1.10) 0.119
Other diseases 0.81 (0.62 to 1.05) 0.114
Total 0.82 (0.65 to 1.04) 0.100
  Outpatient services Diseases of the musculoskeletal system and connective tissue 1.05 (1.00 to 1.10) 0.057
Other diseases 1.24 (1.09 to 1.41) 0.001
Total 1.07 (1.03 to 1.12) 0.001
  Primary sector General practitioner 1.03 (0.99 to 1.08) 0.130
Other practicing specialist 0.97 (0.85 to 1.10) 0.603
Physiotherapist, chiropractor, foot specialist 0.97 (0.92 to 1.02) 0.258
Other 0.94 (0.88 to 1.02) 0.140
Total 0.99 (0.95 to 1.02) 0.426
  Medication Pain medication 0.98 (0.93 to 1.03) 0.331
Other medication 0.95 (0.91 to 1.00) 0.061
Total 0.95 (0.92 to 0.99) 0.019
Total costs 1.04 (0.99 to 1.09) 0.138
Statistically significant results are marked with bold types.
*Adjusted for gender, age, dead in post period, duration of ETA before index date, stopped SB4 treatment within 180 days and comorbidities 
(WHO chapters) 12–24 months before index date.
†Defined daily dose of medication total costs (DDD).
changes in health utilisation and costs after the switch
There was an 8% increase in number of outpatient visits 
after the switch (estimate 1.08 (95% CI 1.05 to 1.11)). On 
the other hand, number of inpatient days and number of 
days in hospital decreased (table 3) keeping in mind that 
the total number of patients with inpatient services was 
low (table 2).
There was a 7% increase in costs of outpatient services 
after the switch due to a 24% increase in costs unrelated 
to diseases of the musculoskeletal system and connec-
tive tissue (table 3). Prescription medication total costs 
decreased 5% after switch.
Population characteristics influencing change in health utilisation 
and costs after switch
Gender had no influence on changes in health utilisation 
or costs after switching (table 4). Higher age (3% per 
year increase) was associated with higher inpatient total 
costs related to diseases of the musculoskeletal system 
and connective tissue diseases (table 4).
Longer duration of ETA treatment before switch was 
related to increased number of outpatient visits after 
switch (1.07 (1.05–1.19)), higher outpatient total costs 
(1.04, p=0.036) and costs related to general practitioners 
(1.04 (1.01–1.08)).
We also tested whether previous comorbidities were 
associated with changes in health utilisation and health 
costs (see online supplementary table 1A,B). Thus, 
comorbidities with estimates below one was associated 
with a decrease whereas estimates above one was associ-
ated with increase. Overall, there was no signal that any 
comorbidity was associated with changes in both health 
utilisation and costs.
dIsCussIOn
In this observational study of 1620 patients who switched 
from originator to biosimilar etanercept following a 
mandatory nationwide guideline, we detected no nega-
tive impact of the switch on the use and costs of a range 
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of healthcare services during the first year. The fluctua-
tions in the monthly use of services were similar during 
1 year before and after the switch, and although there 
was a minor increase in the use and costs of outpatient 
services, there were on the other hand decreases in the 
use of inpatient services and (other than biological) 
medication costs.
The efficacy and safety of biosimilars have been demon-
strated in randomised clinical trials on marketing.3 
Recent consensus-based recommendations from the 
European League Against Rheumatism stated that 
biosimilars should be considered equal to their bio-orig-
inators.25 However, performance of biosimilars when 
extrapolating across indications or especially when 
switching long-term treated patients in remission has 
been a subject of debate.26–28 Thus, there has been a 
great interest in exploring these matters in observational 
studies of patients in routine care as these would allow 
investigation of large scale switch-outcomes in patients 
with inflammatory arthritis.29 30
We have previously demonstrated that the nationwide 
Danish mandatory switch from originator to biosimilar 
etanercept had no negative impact on disease activity and 
flare rates within 6 months after the switch.12 However, 
patient related factors and non-specific drug effects 
seemed to affect retention to biosimilar—as previously 
demonstrated in other switch cohorts.15 31 The exis-
tence of a nocebo effect that is, poor performance of a 
treatment due to negative expectations has been widely 
discussed when it comes to the biosimilar biological treat-
ments.7 26 28 32 Thus, it has been demonstrated that patients 
and physicians may be reluctant to use the biosimilars.6 It 
might be speculated if existence of a nocebo effect might 
cause a higher need for consultations in inpatient care 
following the switch due to higher need for guidance and 
education. In the current study, there was a slight (7%) 
increase in costs of inpatient services following the switch 
which was mainly associated with non-musculoskeletal 
diseases. Bearing in mind that services provided on the 
switch-date was attributed to the post-switch period, there 
seemed to be was no strong evidence of a higher need of 
consultations following the switch. The optimum strategy 
for performing switch to biosimilar in routine care has 
been discussed and switching has been feared to have a 
negative impact on the patient–physician relationship.17 
Shared decision making and non-mandatory switch 
procedures in order to include the patients’ perspectives 
in the switch process might potentially improve switch 
outcomes.17 33 Notably, no extra resources or specific 
education were allocated to the healthcare personnel in 
Denmark in relation to performing the switch from orig-
inator to biosimilar etanercept. It was beyond the scope 
of our study to explore these aspects of the switch process 
further.
This study adds important new knowledge to the 
emerging pool of outcome studies of biosimilar switch 
by investigating the impact on healthcare use and costs. 
We investigated whether we could identify any patient 
population that experienced changes in use and costs 
of healthcare services following the switch. We found 
an increasing use in patients that had previously been 
treated with ETA for a longer time-period—however, 
this only applied to outpatient, not to other services. The 
impact of higher age was less clear, whereas gender and 
comorbidities were unassociated. This might illustrate 
that patients that have been treated with ETA for several 
years deserve extra attention during the switch process. 
Results must however be interpreted with caution due to 
few in-hospital services during the study period.
We have previously investigated the impact of 
non-medical switch on the use of healthcare resources 
among patients with inflammatory arthritis treated with 
infliximab—and concluded that no major changes could 
be observed.16 Those previous data focused on services 
provided in outpatient rheumatology care. In the present 
study we expanded the health-economic investigation to 
include inpatient care, use of medications other that the 
bio-similar and services provided in the primary sector.
The study has strengths and limitations to consider. 
DANBIO is virtually complete (>95%) when it comes to 
the registration and monitoring of patients treated with 
biological DMARDs. All Danish departments of rheuma-
tology were invited to specifically validate the treatment 
and the switch date. By use of social security numbers, 
linkage to other national registries was possible. The 
strength of these registries are high completeness and 
unbiased prospective collection of data in the Danish 
population. In the calculation of average healthcare 
costs and resources we defined a ‘standard person’ 
as a 55 years old woman, not dead in the post-switch 
period, not withdrawn from SB4 within 0–180 days, with 
previous duration of ETA treatment >5 years and with 
no previous comorbidities. The adjusted averages and 
costs were considerably lower than the corresponding 
unadjusted numbers—probably because many patients 
had comorbidities and these are associated with higher 
use of resources. Patients served as their own controls in 
the statistical analyses of use before and after the switch. 
Thus, confounding by indication (ie, the decision to 
switch to treatment with SB4) is expected to be minimal. 
The medication costs of ETA and SB4 were not included 
in the calculation of healthcare costs since biological 
treatments were not provided by prescription but by the 
hospital. In addition, the drug prices were not publicly 
available.
In conclusion, following a nationwide mandatory 
non-medical switch from originator to biosimilar etaner-
cept we demonstrated no obvious changes in use and 
costs of healthcare services during the first year after the 
switch.
author affiliations
1DanBiO and copenhagen center for arthritis research (cOPecare), center for 
rheumatology and Spine Diseases, centre of Head and Orthopedics, rigshospitalet, 
Kobenhavn, Denmark
2Department of clinical Medicine, Faculty of Health Sciences, University of 
copenhagen, Kobenhavn, Denmark
Protected by copyright.
 o
n
 D
ecem
ber 19, 2019 at Kobenhavns Universitets Bibliotek.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2019-001016 on 12 August 2019. Downloaded from
 
9glintborg B, et al. RMD Open 2019;5:e001016. doi:10.1136/rmdopen-2019-001016
Treatments
3i2minds, aarhus, Denmark
4the Danish centre for Social Science research, copenhagen, Denmark
acknowledgements We thank all the Danish departments of rheumatology, which 
report to the DanBiO registry. especially we would like to thank the colleagues, 
who validated the switch dates in DanBiO: anne gitte loft, emina Omerovic, Oliver 
Hendricks, asta linauskas, Jakob espesen, Kamilla Danebod, Dorte Vendelbo 
Jensen, Henrik nordin, emil Barner Dalgaard, Stavros chrysidis, Salome Kristensen, 
Johnny lillelund raun, Hanne lindegaard, natalia Manilo, Susanne Højmark 
Jakobsen, inger Marie Jensen Hansen, Dorte Dalsgaard Pedersen, inge Juul 
Sørensen, lis Smedegaard andersen, Jolanta grydehøj. the work of it consultant 
niels Steen Krogh, Zitelab aps, who extracted data from DanBiO is acknowledged.
Contributors ri and JK performed analysis of raw data. Bg contributed 
interpretation of data from DanBiO. all authors contributed to study design, 
interpretation of results and the preparation of manuscript.
Funding the study was partly funded by Pfizer, who had no access to raw data 
and had no influence on the preparation of this manuscript or on the decision to 
publish these data.
Competing interests Bg: abbvie, Biogen, Pfizer. MH: abbvie, Biogen, BMS, 
celltrion, MSD, novartis, Orion, Pfizer, Samsung, UcB. JK: novo nordisk, Pfizer, 
roche, celgene.
Patient consent for publication not required.
Provenance and peer review not commissioned; externally peer reviewed.
data availability statement all data relevant to the study are included in the 
article or uploaded as supplementary information.
Open access this is an open access article distributed in accordance with the 
creative commons attribution non commercial (cc BY-nc 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the 
use is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
RefeRences
 1. Dörner T, Strand V, Cornes P, et al. The changing landscape of 
biosimilars in rheumatology. Ann Rheum Dis 2016;75:974–82.
 2. Gerdes S, Thaçi D, Griffiths CEM, et al. Multiple switches between 
GP2015, an etanercept biosimilar, with originator product do 
not impact efficacy, safety and immunogenicity in patients with 
chronic plaque-type psoriasis: 30-week results from the phase 
3, confirmatory EGALITY study. J Eur Acad Dermatol Venereol 
2018;32:420–7.
 3. Emery P, Vencovský J, Sylwestrzak A, et al. A phase III randomised, 
double-blind, parallel-group study comparing SB4 with etanercept 
reference product in patients with active rheumatoid arthritis despite 
methotrexate therapy. Ann Rheum Dis 2017;76:51–7.
 4. Gulácsi L, Brodszky V, Baji P, et al. Biosimilars for the management 
of rheumatoid arthritis: economic considerations. Expert Rev Clin 
Immunol 2015;11:43–52.
 5. Kristensen LE, Alten R, Puig L, et al. Non-Pharmacological effects in 
switching medication: the nocebo effect in switching from Originator 
to Biosimilar agent. BioDrugs 2018;32:397–404.
 6. Waller J, Sullivan E, Piercy J, et al. Assessing physician and 
patient acceptance of infliximab biosimilars in rheumatoid arthritis, 
ankylosing spondyloarthritis and psoriatic arthritis across Germany. 
Patient Prefer Adherence 2017;11:519–30.
 7. Odinet JS, Day CE, Cruz JL, et al. The Biosimilar nocebo effect? A 
systematic review of double-blinded versus open-label studies. J 
Manag Care Spec Pharm 2018;24:952–9.
 8. Rezk MF, Pieper B. Treatment outcomes with biosimilars: be aware 
of the nocebo effect. Rheumatol Ther 2017;4:209–18.
 9. Araújo FC, Gonçalves J, Fonseca JE. Pharmacoeconomics of 
biosimilars: what is there to gain from them? Curr Rheumatol Rep 
2016;18:50.
 10. The Danish regions, rads, guidelines for use of biosimilar infliximab 
and etanercept. Available: http://www. regioner. dk/ media/ 3488/ rads- 
notat- om- anvendelsen- af- biosimilaere- juni- 2016. pdf [Accessed May 
2019].
 11. Ibfelt EH, Jensen DV, Hetland ML. The Danish nationwide clinical 
register for patients with rheumatoid arthritis: DANBIO. Clin 
Epidemiol 2016;8:737–42.
 12. Glintborg B, Loft AG, Omerovic E, et al. To switch or not to switch: 
results of a nationwide guideline of mandatory switching from 
originator to biosimilar etanercept. one-year treatment outcomes in 
2061 patients with inflammatory arthritis from the DANBIO registry. 
Ann Rheum Dis 2019;78:192–200.
 13. Hetland ML. DANBIO-powerful research database and electronic 
patient record. Rheumatology 2011;50:69–77.
 14. Lynge E, Sandegaard JL, Rebolj M. The Danish national patient 
register. Scand J Public Health 2011;39(7 Suppl):30–3.
 15. Glintborg B, Sørensen IJ, Loft AG, et al. A nationwide non-medical 
switch from originator infliximab to biosimilar CT-P13 in 802 patients 
with inflammatory arthritis: 1-year clinical outcomes from the 
DANBIO registry. Ann Rheum Dis 2017;76:1426–31.
 16. Glintborg B, Sørensen J, Hetland ML. Does a mandatory non-
medical switch from originator to biosimilar infliximab lead to 
increased use of outpatient healthcare resources? A register-
based study in patients with inflammatory arthritis. RMD Open 
2018;4:e000710.
 17. Scherlinger M, Langlois E, Germain V, et al. Acceptance rate 
and sociological factors involved in the switch from originator to 
biosimilar etanercept (SB4). Semin Arthritis Rheum 2019;48:927–32.
 18. http://www. esundhed. dk/ dokumentation/ Registre/ Sider/ Variabel. 
aspx? rp: A_ Register= 14& rp: B_ Tabel= 63& rp: C_ Variabel= 399& 
[Accessed May 2019].
 19. Johannesdottir SA, Horváth-Puhó E, Ehrenstein V, et al. Existing 
data sources for clinical epidemiology: the Danish national database 
of Reimbursed prescriptions. Clin Epidemiol 2012;4:303–13.
 20. Webpage, Sundhedsdatastyrelsen. Available: https:// sund heds data 
styr elsen. dk/ da/ afregning- og- finansiering/ takster- drg/ takster- 2016 
[Accessed May 2019].
 21. https:// sund heds data styr elsen. dk/ da/ registre- og- services/ om- de- 
nationale- sundhedsregistre/ sundhedsoekonomi- og- finansiering/ 
syge sikr ings regi steret [Accessed May 2019].
 22. https:// en. wikipedia. org/ wiki/ Health_ 21 [Accessed May 2019].
 23. Buntin MB, Zaslavsky AM. Too much ado about two-part models 
and transformation? Comparing methods of modeling Medicare 
expenditures. J Health Econ 2004;23:525–42.
 24. Wang M. Generalized estimating equations in longitudinal 
data analysis: a review and recent developments. Adv Stat 
2014;2014:1–11.
 25. Kay J, Schoels MM, Dörner T, et al. Consensus-Based 
recommendations for the use of biosimilars to treat rheumatological 
diseases. Ann Rheum Dis 2018;77:165–74.
 26. Cantini F, Benucci M. Switching from the bio-originators to 
biosimilar: is it premature to recommend this procedure? Ann 
Rheum Dis 2019;78:e23.
 27. Fleischmann R. Editorial: The American College of Rheumatology 
white paper on biosimilars: it isn't all white-there is some gray and 
black. Arthritis Rheumatol 2018;70:323–5.
 28. Cantini F, Benucci M. Mandatory, cost-driven switching from 
originator etanercept to its biosimilar SB
4: possible fallout on 
non-medical switching. Ann Rheum Dis 2018. doi: 10.1136/
annrheumdis-2018-214757. [Epub ahead of print 28 Nov 2018].
 29. Uhlig T, Goll GL. Reviewing the evidence for biosimilars: key 
insights, lessons learned and future horizons. Rheumatology 
2017;56(suppl_4):iv49–62.
 30. Kay J, Dörner T, Emery P, et al. Clinical trial and ‘real-world’ data 
support switching from a bio-originator to its biosimilar. Ann Rheum 
Dis 2019. doi: 10.1136/annrheumdis-2018-214994. [Epub ahead of 
print 18 Jan 2019].
 31. Tweehuysen L, van den Bemt BJF, van Ingen IL, et al. Subjective 
complaints as the main reason for Biosimilar discontinuation 
after open-label transition from reference infliximab to Biosimilar 
infliximab. Arthritis Rheumatol 2018;70:60–8.
 32. Scherlinger M, Germain V, Labadie C, et al. Switching from originator 
infliximab to biosimilar CT-P13 in real-life: the weight of patient 
acceptance. Joint Bone Spine 2018;85:561–7.
 33. Scherlinger M, Schaeverbeke T. 'To switch or not to switch': the 
missing piece in the puzzle of biosimilar literature? Ann Rheum Dis 
2019. doi: 10.1136/annrheumdis-2018-214908. [Epub ahead of print 
4 Jan 2019].
Protected by copyright.
 o
n
 D
ecem
ber 19, 2019 at Kobenhavns Universitets Bibliotek.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2019-001016 on 12 August 2019. Downloaded from
 
